title: Clinical overview of Fanhdi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors.
authors.affiliation: Hematology Department, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Madrid, Spain.
authors.forename: V
authors.initials: V
authors.lastname: Jiménez-Yuste
authors.affiliation: Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Oldenburg
authors.affiliation: Hampshire Hospitals NHS Trust, Basingstoke, UK.
authors.forename: S
authors.initials: S
authors.lastname: Rangarajan
authors.affiliation: Pediatric Hematology and Oncology, Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, USA.
authors.forename: M H
authors.initials: MH
authors.lastname: Kurth
authors.affiliation: Scientific and Medical Affairs, Grifols, Sant Cugat del Vallès, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Bozzo
authors.affiliation: Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Cà Granda Foundation, Ospedale Maggiore Policlinico, Milan, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Santagostino
mesh_terms: D002986:Clinical Trials as Topic; D004338:Drug Combinations; D005169:Factor VIII / Q000494:pharmacology* / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects*; D014841:von Willebrand Factor / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; C509423:factor VIII, von Willebrand factor drug combination; D014841:von Willebrand Factor; D005169:Factor VIII